Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: A network meta-analysis for efficacies and toxicities of different concurrent chemoradiotherapy regimens in the treatment of locally advanced non-small cell lung cancer

Fig. 2

Network evidence plots of different CCRT regimens. A Network evidence plots of ORR and OS of different CCRT regimens. B Network evidence plots of toxicities of different CCRT regimens. The width of the lines is proportional to the number of trials comparing every pair of treatments, and the size of every circle is proportional to the number of randomly assigned participants (sample size). A = CCRT (cisplatin + etoposide). B = CCRT (carboplatin + paclitaxel). C = CCRT (pemetrexed + carboplatin). CCRT = concurrent chemoradiotherapy. D = CCRT (pemetrexed + cisplatin). E = CCRT (docetaxel + cisplatin). F = CCRT (S-1 + cisplatin). G = CCRT (mitomycin + vindesine + cisplatin). H = CCRT (cisplatin + vinorelbine). I = CCRT (cisplatin). J = CCRT (etoposide + cisplatin + amifostine). K = RT. L = CCRT (5-FU). M = CCRT (paclitaxel + cisplatin). N = CCRT (irinotecan + carboplatin). NMA = network meta-analysis. O = CCRT (nedaplatin). ORR = overall response rate. OS = overall survival. P = CCRT (carboplatin + etoposide). Q = CCRT (paclitaxel). R = CCRT (carboplatin)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us